This brand name is authorized in United States. It is also authorized in Austria, Croatia, Cyprus, Estonia, Finland, France, Ireland, Israel, Italy, Lithuania, Netherlands, Poland, Romania, Spain, UK.
The drug VYXEOS LIPOSOMAL contains a combination of these active pharmaceutical ingredients (APIs):
1
|
UNII
ZS7284E0ZP - DAUNORUBICIN
|
|
Daunorubicin is an anthracycline glycoside antibiotic and is a potent antileukaemic agent. It also has immunosuppressant effects. Daunorubicin may involve binding to DNA by intercalation between base pairs and inhibition of DNA and RNA synthesis by template disordering and steric obstruction. |
|
2
|
UNII
04079A1RDZ - CYTARABINE
|
|
Cytarabine (ARA-C) is metabolised in vivo to ARA-CTP phosphorylated compound. This competitively inhibits DNA polymerase and may also inhibit certain acid kinase enzymes. |
|
Below package inserts are available for further reading:
| Document | Type | Information Source | |
|---|---|---|---|
| VYXEOS LIPOSOMAL Powder for concentrate for solution for infusion | MPI, EU: SmPC |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| L01XY01 | L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XY Combinations of antineoplastic agents | |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| EE | Ravimiamet | 1778362, 1778373, 1778384 |
| ES | Centro de información online de medicamentos de la AEMPS | 1181308001 |
| FI | Lääkealan turvallisuus- ja kehittämiskeskus | 063574 |
| FR | Base de données publique des médicaments | 63280448 |
| GB | Medicines & Healthcare Products Regulatory Agency | 357784 |
| IL | מִשְׂרַד הַבְּרִיאוּת | 9041 |
| IT | Agenzia del Farmaco | 046965012, 046965024, 046965036 |
| LT | Valstybinė vaistų kontrolės tarnyba | 1086210, 1086211, 1086212 |
| PL | Rejestru Produktów Leczniczych | 100410692 |
| RO | Agenția Națională a Medicamentului și a Dispozitivelor Medicale | W68462001, W68462002, W68462003, W69088001 |
| US | FDA, National Drug Code | 68727-745 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.